Skip to content

Comparative Clinical Study To Evaluate The Efficacy Of Chaturbhadra Kwath With Panchamrita Parpati Vati In The Management Of Grahani.

Randomized Controlled Comparative Clinical Study To Evaluate The Efficacy Of Chaturbhadra Kwath With Panchamrita Parpati Vati In The Management Of Grahani. - Nil

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/06/053939
Enrollment
100
Registered
2023-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K582- Mixed irritable bowel syndrome

Interventions

None listed

Sponsors

Dr Aishwarya Karandikar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed patients fulfilling the subjective criteria of Grahanidosha. Muhur Baddha, Muhur Drava Mala Pravritti, Aruchi, Udarshool, Prasek, Udgara Pravritti, Trishna, Arochak, Vidaha, Pada Shoth, Aalasya, Tama Pravesh, Balakshaya, Chardi.

Exclusion criteria

Exclusion criteria: Patients suffering from acute diarrhoea, intestinal tuberculosis, ulcerative colitis, gastric and peptic ulcer, strictures, colonic cancer, toxic mega colon, pregnancy, haemorrhage , perforation, immune-compromised, uncontrolled diabetes.

Design outcomes

Primary

MeasureTime frame
Relief from the subjective assessment criteria i.e clinical signs and symptoms of Grahani like Muhur Baddha/Muhur Drava Mala pravritti, Mala Swaroop, Udgara Pravritti, Trishna, Arochaka, Vidaha, Pada Shoth, Aalasya,Tama Pravesh, Prasek, Bala Kshay and Chardi.Timepoint: The outcome will be assessed at baseline, 15th day and 30th day

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Ashish Mhatre

Padmashri Dr D. Y. Patil University, School of Ayurveda

ashishmhatre2010@gmail.com9819639895

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026